Ligand Pharmaceuticals Inc
LGND· Nasdaq
LGNDLigand Pharmaceuticals Inc
Filed Feb 28, 2017 · 10-K · 59 days after period end · 0000886163-17-000021
| Metric | Q4 2016 | Q4 2015 | Q4 2012 | Q4 2011dderived from reported figures |
|---|---|---|---|---|
| Revenue | $38.19M | $21.19M | $6.38M | $13.64M |
| Net Income | -$3.13M | $6.34M | -$194.00K | $1.06M |
| EPS Diluted | $0.15 | $0.29 | -$0.01 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
ended Dec 31, 2016 · filed Feb 28, 2017 · 59 d after period end
